These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38574200)

  • 1. Preserved striatal innervation maintains motor function despite severe loss of nigral dopaminergic neurons.
    Paß T; Ricke KM; Hofmann P; Chowdhury RS; Nie Y; Chinnery P; Endepols H; Neumaier B; Carvalho A; Rigoux L; Steculorum SM; Prudent J; Riemer T; Aswendt M; Liss B; Brachvogel B; Wiesner RJ
    Brain; 2024 Sep; 147(9):3189-3203. PubMed ID: 38574200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
    Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
    Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant Twinkle increases dopaminergic neurodegeneration, mtDNA deletions and modulates Parkin expression.
    Song L; Shan Y; Lloyd KC; Cortopassi GA
    Hum Mol Genet; 2012 Dec; 21(23):5147-58. PubMed ID: 22949510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease.
    Nordströma U; Beauvais G; Ghosh A; Pulikkaparambil Sasidharan BC; Lundblad M; Fuchs J; Joshi RL; Lipton JW; Roholt A; Medicetty S; Feinstein TN; Steiner JA; Escobar Galvis ML; Prochiantz A; Brundin P
    Neurobiol Dis; 2015 Jan; 73():70-82. PubMed ID: 25281317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Absence of Parkin Does Not Promote Dopamine or Mitochondrial Dysfunction in PolgA
    Scott L; Karuppagounder SS; Neifert S; Kang BG; Wang H; Dawson VL; Dawson TM
    J Neurosci; 2022 Dec; 42(49):9263-9277. PubMed ID: 36280265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining.
    Ares-Santos S; Granado N; Espadas I; Martinez-Murillo R; Moratalla R
    Neuropsychopharmacology; 2014 Apr; 39(5):1066-80. PubMed ID: 24169803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manganese exposure exacerbates progressive motor deficits and neurodegeneration in the MitoPark mouse model of Parkinson's disease: Relevance to gene and environment interactions in metal neurotoxicity.
    Langley MR; Ghaisas S; Ay M; Luo J; Palanisamy BN; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    Neurotoxicology; 2018 Jan; 64():240-255. PubMed ID: 28595911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe nigrostriatal degeneration without clinical parkinsonism in patients with polymerase gamma mutations.
    Tzoulis C; Tran GT; Schwarzlmüller T; Specht K; Haugarvoll K; Balafkan N; Lilleng PK; Miletic H; Biermann M; Bindoff LA
    Brain; 2013 Aug; 136(Pt 8):2393-404. PubMed ID: 23625061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons.
    Choi WS; Kim HW; Tronche F; Palmiter RD; Storm DR; Xia Z
    Sci Rep; 2017 Mar; 7():44989. PubMed ID: 28327638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accumulation of Cholesterol and Homocysteine in the Nigrostriatal Pathway of Brain Contributes to the Dopaminergic Neurodegeneration in Mice.
    Paul R; Dutta A; Phukan BC; Mazumder MK; Justin-Thenmozhi A; Manivasagam T; Bhattacharya P; Borah A
    Neuroscience; 2018 Sep; 388():347-356. PubMed ID: 30075243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
    Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
    Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chondroitinase ABC reduces dopaminergic nigral cell death and striatal terminal loss in a 6-hydroxydopamine partial lesion mouse model of Parkinson's disease.
    Fletcher EJR; Moon LDF; Duty S
    BMC Neurosci; 2019 Dec; 20(1):61. PubMed ID: 31862005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Native DIGE proteomic analysis of mitochondria from substantia nigra and striatum during neuronal degeneration and its compensation in an animal model of early Parkinson's disease.
    Kuter K; Kratochwil M; Marx SH; Hartwig S; Lehr S; Sugawa MD; Dencher NA
    Arch Physiol Biochem; 2016 Dec; 122(5):238-256. PubMed ID: 27467289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
    Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
    Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopaminergic Axons: Key Recitalists in Parkinson's Disease.
    Mishra AK; Dixit A
    Neurochem Res; 2022 Feb; 47(2):234-248. PubMed ID: 34637100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study.
    Blesa J; Pifl C; Sánchez-González MA; Juri C; García-Cabezas MA; Adánez R; Iglesias E; Collantes M; Peñuelas I; Sánchez-Hernández JJ; Rodríguez-Oroz MC; Avendaño C; Hornykiewicz O; Cavada C; Obeso JA
    Neurobiol Dis; 2012 Oct; 48(1):79-91. PubMed ID: 22677034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Striatal dysfunctions associated with mitochondrial DNA damage in dopaminergic neurons in a mouse model of Parkinson's disease.
    Pickrell AM; Pinto M; Hida A; Moraes CT
    J Neurosci; 2011 Nov; 31(48):17649-58. PubMed ID: 22131425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mfn2 protects dopaminergic neurons exposed to paraquat both in vitro and in vivo: Implications for idiopathic Parkinson's disease.
    Zhao F; Wang W; Wang C; Siedlak SL; Fujioka H; Tang B; Zhu X
    Biochim Biophys Acta Mol Basis Dis; 2017 Jun; 1863(6):1359-1370. PubMed ID: 28215578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.